Sagar Cements Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 28, 2025, 9:18 am

Competitors of Sagar Cements Ltd

All Competitor Stocks of Sagar Cements Ltd

Quarterly Result

Last Updated: August 1, 2025, 12:55 pm

Below is a detailed analysis of the quarterly data for Sagar Cements Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 670.66 Cr.. The value appears strong and on an upward trend. It has increased from 658.04 Cr. (Mar 2025) to 670.66 Cr., marking an increase of 12.62 Cr..
• For Expenses, as of Jun 2025, the value is 549.21 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 621.22 Cr. (Mar 2025) to 549.21 Cr., marking a decrease of 72.01 Cr..
• For Operating Profit, as of Jun 2025, the value is 121.45 Cr.. The value appears strong and on an upward trend. It has increased from 36.82 Cr. (Mar 2025) to 121.45 Cr., marking an increase of 84.63 Cr..
• For OPM %, as of Jun 2025, the value is 18.11%. The value appears strong and on an upward trend. It has increased from 5.60% (Mar 2025) to 18.11%, marking an increase of 12.51%.
• For Other Income, as of Jun 2025, the value is 4.19 Cr.. The value appears strong and on an upward trend. It has increased from -23.69 Cr. (Mar 2025) to 4.19 Cr., marking an increase of 27.88 Cr..
• For Interest, as of Jun 2025, the value is 47.09 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 47.31 Cr. (Mar 2025) to 47.09 Cr., marking a decrease of 0.22 Cr..
• For Depreciation, as of Jun 2025, the value is 54.65 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 58.36 Cr. (Mar 2025) to 54.65 Cr., marking a decrease of 3.71 Cr..
• For Profit before tax, as of Jun 2025, the value is 23.90 Cr.. The value appears strong and on an upward trend. It has increased from -92.54 Cr. (Mar 2025) to 23.90 Cr., marking an increase of 116.44 Cr..
• For Tax %, as of Jun 2025, the value is 68.66%. The value appears to be increasing, which may not be favorable. It has increased from -21.06% (Mar 2025) to 68.66%, marking an increase of 89.72%.
• For Net Profit, as of Jun 2025, the value is 7.49 Cr.. The value appears strong and on an upward trend. It has increased from -73.05 Cr. (Mar 2025) to 7.49 Cr., marking an increase of 80.54 Cr..
• For EPS in Rs, as of Jun 2025, the value is 0.09. The value appears strong and on an upward trend. It has increased from -5.41 (Mar 2025) to 0.09, marking an increase of 5.50.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: November 15, 2025, 4:32 am

Growth

Last Updated: September 5, 2025, 1:15 pm

Balance Sheet

Last Updated: November 9, 2025, 2:51 pm

Below is a detailed analysis of the balance sheet data for Sagar Cements Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

• For Equity Capital, as of Sep 2025, the value is 26.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 26.00 Cr..
• For Reserves, as of Sep 2025, the value is 1,656.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,697.00 Cr. (Mar 2025) to 1,656.00 Cr., marking a decrease of 41.00 Cr..
• For Borrowings, as of Sep 2025, the value is 1,640.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 1,448.00 Cr. (Mar 2025) to 1,640.00 Cr., marking an increase of 192.00 Cr..
• For Other Liabilities, as of Sep 2025, the value is 1,074.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 950.00 Cr. (Mar 2025) to 1,074.00 Cr., marking an increase of 124.00 Cr..
• For Total Liabilities, as of Sep 2025, the value is 4,396.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4,121.00 Cr. (Mar 2025) to 4,396.00 Cr., marking an increase of 275.00 Cr..
• For Fixed Assets, as of Sep 2025, the value is 3,041.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3,109.00 Cr. (Mar 2025) to 3,041.00 Cr., marking a decrease of 68.00 Cr..
• For CWIP, as of Sep 2025, the value is 316.00 Cr.. The value appears strong and on an upward trend. It has increased from 123.00 Cr. (Mar 2025) to 316.00 Cr., marking an increase of 193.00 Cr..
• For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
• For Other Assets, as of Sep 2025, the value is 1,039.00 Cr.. The value appears strong and on an upward trend. It has increased from 889.00 Cr. (Mar 2025) to 1,039.00 Cr., marking an increase of 150.00 Cr..
• For Total Assets, as of Sep 2025, the value is 4,396.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,121.00 Cr. (Mar 2025) to 4,396.00 Cr., marking an increase of 275.00 Cr..

Notably, the Reserves (1,656.00 Cr.) exceed the Borrowings (1,640.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Sagar Cements Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
• For Basic EPS (Rs.), as of Mar 25, the value is -16.58. This value is below the healthy minimum of 5. It has decreased from -3.98 (Mar 24) to -16.58, marking a decrease of 12.60.
• For Diluted EPS (Rs.), as of Mar 25, the value is -16.58. This value is below the healthy minimum of 5. It has decreased from -3.98 (Mar 24) to -16.58, marking a decrease of 12.60.
• For Cash EPS (Rs.), as of Mar 25, the value is 1.08. This value is below the healthy minimum of 3. It has decreased from 12.40 (Mar 24) to 1.08, marking a decrease of 11.32.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 131.81. It has decreased from 154.53 (Mar 24) to 131.81, marking a decrease of 22.72.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 131.81. It has decreased from 154.53 (Mar 24) to 131.81, marking a decrease of 22.72.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 172.73. It has decreased from 191.63 (Mar 24) to 172.73, marking a decrease of 18.90.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 12.43. This value is within the healthy range. It has decreased from 22.96 (Mar 24) to 12.43, marking a decrease of 10.53.
• For PBIT / Share (Rs.), as of Mar 25, the value is -5.22. This value is below the healthy minimum of 0. It has decreased from 6.57 (Mar 24) to -5.22, marking a decrease of 11.79.
• For PBT / Share (Rs.), as of Mar 25, the value is -21.69. This value is below the healthy minimum of 0. It has decreased from -6.44 (Mar 24) to -21.69, marking a decrease of 15.25.
• For Net Profit / Share (Rs.), as of Mar 25, the value is -16.58. This value is below the healthy minimum of 2. It has decreased from -3.98 (Mar 24) to -16.58, marking a decrease of 12.60.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -16.05. This value is below the healthy minimum of 2. It has decreased from -3.32 (Mar 24) to -16.05, marking a decrease of 12.73.
• For PBDIT Margin (%), as of Mar 25, the value is 7.19. This value is below the healthy minimum of 10. It has decreased from 11.97 (Mar 24) to 7.19, marking a decrease of 4.78.
• For PBIT Margin (%), as of Mar 25, the value is -3.02. This value is below the healthy minimum of 10. It has decreased from 3.43 (Mar 24) to -3.02, marking a decrease of 6.45.
• For PBT Margin (%), as of Mar 25, the value is -12.55. This value is below the healthy minimum of 10. It has decreased from -3.35 (Mar 24) to -12.55, marking a decrease of 9.20.
• For Net Profit Margin (%), as of Mar 25, the value is -9.59. This value is below the healthy minimum of 5. It has decreased from -2.07 (Mar 24) to -9.59, marking a decrease of 7.52.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is -9.29. This value is below the healthy minimum of 8. It has decreased from -1.73 (Mar 24) to -9.29, marking a decrease of 7.56.
• For Return on Networth / Equity (%), as of Mar 25, the value is -12.17. This value is below the healthy minimum of 15. It has decreased from -2.23 (Mar 24) to -12.17, marking a decrease of 9.94.
• For Return on Capital Employeed (%), as of Mar 25, the value is -2.29. This value is below the healthy minimum of 10. It has decreased from 2.56 (Mar 24) to -2.29, marking a decrease of 4.85.
• For Return On Assets (%), as of Mar 25, the value is -5.02. This value is below the healthy minimum of 5. It has decreased from -0.99 (Mar 24) to -5.02, marking a decrease of 4.03.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.57. This value is within the healthy range. It has increased from 0.56 (Mar 24) to 0.57, marking an increase of 0.01.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.82. This value is within the healthy range. It has increased from 0.74 (Mar 24) to 0.82, marking an increase of 0.08.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.52. It has decreased from 0.61 (Mar 24) to 0.52, marking a decrease of 0.09.
• For Current Ratio (X), as of Mar 25, the value is 0.58. This value is below the healthy minimum of 1.5. It has decreased from 0.85 (Mar 24) to 0.58, marking a decrease of 0.27.
• For Quick Ratio (X), as of Mar 25, the value is 0.35. This value is below the healthy minimum of 1. It has decreased from 0.55 (Mar 24) to 0.35, marking a decrease of 0.20.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.46. This value is below the healthy minimum of 4. It has decreased from 1.59 (Mar 24) to 1.46, marking a decrease of 0.13.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is -4.36. This value is below the healthy minimum of 20. It has increased from -21.10 (Mar 24) to -4.36, marking an increase of 16.74.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 43.65. This value is within the healthy range. It has increased from 5.35 (Mar 24) to 43.65, marking an increase of 38.30.
• For Earning Retention Ratio (%), as of Mar 25, the value is 104.36. This value exceeds the healthy maximum of 70. It has decreased from 121.10 (Mar 24) to 104.36, marking a decrease of 16.74.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 56.35. This value is within the healthy range. It has decreased from 94.65 (Mar 24) to 56.35, marking a decrease of 38.30.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 0.86. This value is below the healthy minimum of 3. It has decreased from 1.62 (Mar 24) to 0.86, marking a decrease of 0.76.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -0.01. This value is below the healthy minimum of 3. It has decreased from 0.63 (Mar 24) to -0.01, marking a decrease of 0.64.
• For Enterprise Value (Cr.), as of Mar 25, the value is 3,682.52. It has decreased from 3,981.14 (Mar 24) to 3,682.52, marking a decrease of 298.62.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.63. This value is within the healthy range. It has increased from 1.59 (Mar 24) to 1.63, marking an increase of 0.04.
• For EV / EBITDA (X), as of Mar 25, the value is 22.66. This value exceeds the healthy maximum of 15. It has increased from 13.27 (Mar 24) to 22.66, marking an increase of 9.39.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.04. This value is within the healthy range. It has decreased from 1.09 (Mar 24) to 1.04, marking a decrease of 0.05.
• For Retention Ratios (%), as of Mar 25, the value is 104.36. This value exceeds the healthy maximum of 70. It has decreased from 121.10 (Mar 24) to 104.36, marking a decrease of 16.74.
• For Price / BV (X), as of Mar 25, the value is 1.36. This value is within the healthy range. It has decreased from 1.40 (Mar 24) to 1.36, marking a decrease of 0.04.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.04. This value is within the healthy range. It has decreased from 1.09 (Mar 24) to 1.04, marking a decrease of 0.05.
• For EarningsYield, as of Mar 25, the value is -0.08. This value is below the healthy minimum of 5. It has decreased from -0.01 (Mar 24) to -0.08, marking a decrease of 0.07.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness